Please ensure Javascript is enabled for purposes of website accessibility

Why Brooklyn ImmunoTherapeutics Crushed the Market Today

By Eric Volkman - Jun 14, 2021 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is bulking up with a new acquisition.

What happened

Shares of Brooklyn ImmunoTherapeutics (BTX -4.24%), no stranger to sharp stock price movements lately, zoomed more than 6% higher on Monday. The catalyst was an acquisition announced that morning by the clincial-stage biotech company.

So what

In a joint press release, Brooklyn and Novellus Therapeutics announced that the former has executed a letter of intent to acquire the latter. The next step is for the two to sign a definite agreement; the letter of intent stipulates that Brooklyn will pay a total of $125 million for privately held Novellus. Of this, nearly $108 million will be paid in Brooklyn stock, with the remainder in cash.

The two companies added that they intend to close the deal on or prior to July 15.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

"This acquisition would further advance Brooklyn's evolution into a platform company with a pipeline of next-generation gene and cell therapy programs," that company's CEO Howard Federoff was quoted as saying.

"We believe Novellus' next-generation engineered [mesenchymal stem cell] platform can position Brooklyn to become a leader in stem cell therapies, with the ability to develop multiple therapeutic candidates rapidly," he added.

Now what

The two companies are not strangers to each other. In April, Brooklyn obtained an exclusive license from Novellus and its peer Factor Bioscience for the use of messenger RNA (mRNA) gene editing and cell therapy technology. Thanks to the proliferation of mRNA-based coronavirus vaccines, this is a hot area in biotech just now, so Brooklyn's deal feels like an opportunistic and clever move.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Brooklyn ImmunoTherapeutics, Inc. Stock Quote
Brooklyn ImmunoTherapeutics, Inc.
BTX
$0.53 (-4.24%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
395%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.